In a phase I study in 20 patients with solid tumors and multiple myeloma, trametinib in combination with the AKT inhibitor afuresertib were poorly tolerated at continuous daily dosing, but tolerable at intermittent dosing schedule [42]. This evidence concerns the gene AKT1 and plasma cell myeloma.